Universe Pharmaceuticals
UPC
Market cap $1.74M

0.2014 USD

+0.0589

41.33%

At close Feb 21, 4:00 PM EST

After hours

0.1756

-0.0258

12.81%

1 day

41.33%

5 days

31.63%

1 month

-60.22%

3 months

-88.75%

6 months

-99.58%

Year to date

-68.70%

1 year

-99.20%

5 years

-99.95%

10 years

-99.95%

About: Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Employees: 225

0

Funds holding %

of 7,139 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

109% more capital invested

Capital invested by funds: $165K [Q3] → $344K (+$179K) [Q4]

23.99% more ownership

Funds ownership: 2.86% [Q3] → 26.85% (+23.99%) [Q4]

56% less funds holding

Funds holding: 9 [Q3] → 4 (-5) [Q4]

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for UPC.

See Analyst Rankings

Financial journalist opinion

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period.

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)

New York, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of its client Universe Pharmaceuticals INC (NASDAQ: UPC) (the “Company”), a pharmaceutical producer and distributor in China.

Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ji'an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

JI'AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024.

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

Why Is Universe Pharmaceuticals (UPC) Stock Down 29% Today?

Universe Pharmaceuticals (NASDAQ: UPC ) stock is falling on Tuesday after the company's shares experienced a rally during the prior day of trading. Shares of UPC closed out Friday up 43.9% without any clear news from the traditional Chinese medicine company.

Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results

JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its financial results for the fiscal year ended September 30, 2023. Mr. Gang Lai, Chairman and Chief Executive Officer of Universe Pharmaceuticals, commented, "Despite market fluctuations and the economic slowdown impacting our business in fiscal year 2023, we continued our efforts to deliver high quality products to our loyal customers.

Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™